Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1

Interventions

Rituximab 63 Cyclophosphamide 37 Brentuximab Vedotin 22 Bendamustine Hydrochloride 22 pembrolizumab 20 fludarabine 20 Gemcitabine 20 Doxorubicin 20 Prednisone 19 ibrutinib 17 Vincristine 16 obinutuzumab 14 Lenalidomide 13 Nivolumab 10 Rifampin 8 parsaclisib 7 duvelisib 7 atezolizumab 7 Vorinostat 7 Dexamethasone 7 Azacitidine 7 spartalizumab 6 loncastuximab tesirine 6 MLN 8237 6 venetoclax 5 ixazomib 5 glofitamab 5 fludarabine phosphate 5 durvalumab 5 acalabrutinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma × TQ-B3525 × Clear all

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡